Streamlining Skyrizi Prior Authorization for Rheumatology

Navigating Skyrizi prior authorization for rheumatology patients, particularly those with psoriatic arthritis, presents unique challenges for efficiency and approval rates. Klivira's platform automates the complex requirements specific to this IL-23 inhibitor.

Rheumatology practices frequently manage a high volume of prior authorizations for advanced biologic therapies like Skyrizi (risankizumab). For revenue cycle directors and PA coordinators, ensuring timely access to these critical treatments while minimizing administrative burden and denials is paramount. Understanding the precise payer requirements and clinical pathways for Skyrizi in rheumatology is key to optimizing workflow and patient care.

Skyrizi in the Rheumatology Treatment Pathway

Skyrizi (risankizumab) is an IL-23 inhibitor indicated for conditions including psoriatic arthritis. As a non-TNF biologic, it often falls later in the treatment pathway, typically after conventional synthetic DMARDs and, frequently, after a trial of one or more TNF-alpha inhibitors. Rheumatology prior authorizations for biologics like Skyrizi are among the highest burden due to the chronic nature of the diseases treated and the cost of these advanced agents.

Key Documentation for Skyrizi PA in Psoriatic Arthritis

Successful prior authorization for Skyrizi in rheumatology hinges on thorough documentation that aligns with payer policies and established clinical guidelines, such as the ACR Treatment Guidelines. Payers commonly require specific clinical evidence to justify the use of advanced biologics like risankizumab, particularly for psoriatic arthritis.

Typical Documentation Requirements Include:

**Diagnosis Documentation:** ICD-10 code with specific disease criteria, such as CASPAR criteria for psoriatic arthritis.
**Disease Activity Assessment:** Objective measures like PASI/BSA for psoriasis component or other relevant scores to demonstrate active disease.
**Prior Conventional DMARD Trial:** Documentation of an adequate trial and failure or contraindication to agents like methotrexate, sulfasalazine, or other csDMARDs.
**Step Therapy Compliance:** Evidence of prior failure of one or two specific TNF-alpha inhibitors, as many payers mandate this sequence before approving non-TNF biologics.
**Screening Completion:** Documentation of pre-initiation screenings, including TB (PPD or IGRA) and hepatitis B/C status, due to the immunosuppressive nature of IL-23 inhibitors.

Common Denial Reasons for Skyrizi Prior Authorization

Denials for Skyrizi prior authorizations in rheumatology often stem from specific gaps in documentation or non-adherence to payer-mandated treatment sequences. Proactively addressing these common pitfalls can significantly improve approval rates and reduce re-submission efforts.

Frequent Denial Triggers Include:

**Step Therapy Not Completed:** Failure to document the required trial and failure of specific prior agents, particularly TNF-alpha inhibitors, in the sequence mandated by the payer.
**Disease Activity Not Documented:** Missing or insufficient objective disease activity scores (e.g., PASI/BSA) to demonstrate active and severe disease.
**Conservative Care Duration Insufficient:** The initial conventional DMARD trial was not sustained for the payer-required duration.
**Screening Documentation Gaps:** Incomplete or missing documentation for pre-biologic screenings like TB, hepatitis, or immunization status.

Klivira's Solution for Rheumatology Biologic PAs

Klivira's platform is engineered to address the specific complexities of rheumatology prior authorizations, including those for Skyrizi. Our system integrates with EMRs to pull necessary clinical data and applies robust, ACR-guideline-aware policy logic to streamline the submission process, minimizing manual effort and improving first-pass approval rates.

Frequently asked questions

What specific diagnostic criteria are typically required for Skyrizi prior authorization for psoriatic arthritis?

For psoriatic arthritis (PsA), payers commonly require documentation of the diagnosis using established criteria, such as the CASPAR (Classification Criteria for Psoriatic Arthritis) criteria, alongside appropriate ICD-10 coding. This ensures the medical necessity is clearly supported by clinical standards.

Is step therapy always a requirement for Skyrizi in rheumatology?

Yes, step therapy is a very common requirement for Skyrizi in rheumatology. Payers frequently mandate a documented trial and failure or contraindication to one or two conventional synthetic DMARDs, followed by one or more TNF-alpha inhibitors, before approving non-TNF biologics like Skyrizi. Klivira's platform incorporates this step therapy logic.

How does Klivira handle the periodic re-authorization for chronic Skyrizi treatment?

Klivira's platform includes a dedicated workflow for periodic re-authorizations, which are typical every 6 or 12 months for chronic biologic treatments like Skyrizi. The system prompts for continuous documentation of disease response and adherence to ongoing payer criteria, ensuring timely re-submissions and continuity of care.

What role do screening documentations play in Skyrizi prior authorization?

Screening documentation is critical for Skyrizi and other immunosuppressive biologics. Payers require proof of pre-initiation screenings, such as TB (PPD or IGRA) and hepatitis B/C, to mitigate risks of reactivation. Incomplete screening documentation is a common reason for PA denials.

Can Klivira differentiate between medical and pharmacy benefit for biologics like Skyrizi?

Klivira's platform is designed to manage the medical versus pharmacy benefit split for biologics. While Skyrizi is typically self-administered under the pharmacy benefit, our system accounts for payer-specific policies and potential shifts in administration mode, ensuring accurate routing and submission regardless of the benefit pathway.